Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Renal Cell Carcinoma
100%
Dendritic Cell Vaccine
100%
Clinical Response
50%
Metastatic Renal Cell Carcinoma (mRCC)
50%
Immune Response
33%
Clinical Effect
16%
Route of Administration
16%
Treatment Strategy
16%
Effective Treatment
16%
Antiangiogenic Therapy
16%
Complete Response
16%
Partial Response
16%
Phase III Clinical Trial
16%
Minimal Residual Disease
16%
Treatment Schedule
16%
Tumor Regression
16%
Neoadjuvant Setting
16%
Vaccine Preparation
16%
Antigen-specific Immune Response
16%
Immunotherapeutic Approaches
16%
Disease Stabilization
16%
Combined Method
16%
Vaccination Therapy
16%
Mixed Response
16%
Tumor Induction
16%
Immune Enhancement
16%
Medicine and Dentistry
Clear Cell Renal Cell Carcinoma
100%
Dendritic Cell
100%
Immune Response
50%
Kidney Metastasis
50%
Disease
16%
Malignant Neoplasm
16%
Clinical Trial
16%
Antigen Specificity
16%
Carcinogenesis
16%
Minimal Residual Disease
16%
Drug Administration Route
16%
Tumor Regression
16%
Antiangiogenic Therapy
16%
Pharmacology, Toxicology and Pharmaceutical Science
Vaccination Policy
100%
Renal Cell Carcinoma
100%
Kidney Metastasis
50%
Malignant Neoplasm
16%
Disease
16%
Clinical Trial
16%
Carcinogenesis
16%
Antiangiogenic Therapy
16%
Tumor Regression
16%
Minimal Residual Disease
16%